An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 152 participants.

Also called NCT02324491

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 152 participants (enrolled count) (from the registry)
Sponsor
Zafgen, Inc. (from the registry)
Registry
  • NCT NCT02324491
Other papers using this trial's data
  • Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial Diabetologia, 2018-09 DOI, PubMed 29992370

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02324491. Randomized; triple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
Condition
Obesity
Intervention (Drug)
ZGN-440 for Injectable Suspension
Intervention (Drug)
ZGN-440 Placebo for Injectable Suspension
Lead sponsor
Zafgen, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02324491
Content hash
9fc203ede5872a5316c4266c371a738bcccd810f2c3974d13ae769ecbdb21b0c